Artivila Therapeutics Completes RMB 150 Million Pre-A Financing to Advance AI-Driven Drug Discovery Platform

VCBeat (WeChat: vcbeat) has learned that on March 31, 2021, Artivila Therapeutics (“Artivila”) announced the completion of its RMB 150 million Pre-A financing round, led by HLC, with participation from Med-Fine Capital and Yijing Capital, among others.

The proceeds from this round of financing will be used to advance and expand the company’s R&D pipeline, optimize its computational and AI R&D platforms, construct new R&D laboratories, and purchase instruments and equipment.

Artivila was co-founded by seasoned drug design experts and R&D management professionals with extensive experience in the biopharmaceutical industry. The founding team possesses many years of expertise in computational chemistry and medicinal chemistry from U.S. biopharmaceutical companies. The company maintains offices in Shenzhen, Beijing, and Boston, USA. Artivila specializes in computation-driven novel drug design and is committed to becoming an AI-driven innovative pharmaceutical enterprise focused on research and development.

Dr. Zhu Zhendong, Chairman of Artivilastated, “We are delighted to have received strong support from the investor consortium led by Hui Capital in this round of financing. Adhering to the philosophy of combining AI with HI (Human Intelligence), Artivila applies novel drug design technologies to target selection and compound design, thereby enhancing the speed and efficiency of new drug development. The rapid establishment of Artivila’s diverse product pipeline is primarily attributable to the integration of AI and HI.”

Dr. Niu Deqiang, CEO of Artivila“Hehongjinghui is a well-known investment institution in the pharmaceutical industry. Receiving joint support from Hehongjinghui, Med-Fine Capital, and other investors in this round represents a critical step toward success for Artivila, marking a strong alliance between the investment and corporate sectors. Leveraging our R&D platform and drug development expertise, Artivila has built a diversified pipeline within less than two years, strategically targeting significant unmet medical needs in areas such as neurodegenerative diseases, autoimmune disorders, and oncology. With the support of this funding round, Artivila will strive to further optimize its platform, advance its pipeline, and accelerate the development of innovative therapies to save lives.”

Honghui Capitalstated, “We are delighted to support the development of Artivila, which boasts a rich and highly forward-looking R&D pipeline. Having engaged in years of academic and business discussions with the founding team, we have confidence in Artivila’s R&D capabilities across multiple therapeutic areas, including neurodegenerative diseases, autoimmune disorders, and oncology, and we look forward to advancing internationally leading innovative drug products.”